Our Science
Leveraging adaptive immune responses to destroy cancerous cells
Scancell targets modifications of proteins and lipids prevalent in cancer to generate potent anti-tumour responses by harnessing the adaptive immune response.
Active Immunotherapies
ImmunoBody®
ImmunoBody® DNA active immunotherapies encode a protein in the form of a modified antibody, which is engineered to express epitopes from a cancer antigen whilst retaining the ability to target activated antigen presenting cells in vivo.
Moditope®
The Moditope® platform is a unique class of potent, peptide active immunotherapies targeting tumour-specific neoantigens via the MHC-II presentation pathway.
Antibodies
Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, as well as AvidiMab® Fc engineering to improve the avidity of antibodies.
GlyMab®
High-affinity tumour specific monoclonal antibodies that target highly differentiated glycans that are preferentially expressed on tumours, validated by outlicensing of two antibodies to Genmab A/S, a global leader in antibody therapeutics.
AvidiMab®
Enhancing the potency and efficacy of any clinical antibody or antibody-based product validated in the ImmunoBody® clinical product iSCIB1+.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.